Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$193.98 USD
-2.44 (-1.24%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $193.81 -0.17 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Ascendis Pharma A/S has a market cap of $12.10B, which represents its share price of $196.42 multiplied by its outstanding shares number of 61.62M. As a large-cap company, ASND's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ASND 193.98 -2.44(-1.24%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Other News for ASND
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pharmaceuticals Inc
Is ASND likely to continue higher? 50 Day Moving Average Support shows up after sliding 0.64%
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Wedbush sees no threat to Ascendis' Yorvipath from competitor data